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Objectives: In this nationwide retrospective study, we analysed species distribution, antimicrobial susceptibility and time to next occurrence of
Achromobacter in Danish cystic ﬁbrosis (CF) patients from 2000 to 2011.
Methods: Thirty-four primary isolates were identiﬁed to species level and subjected to antimicrobial susceptibility testing. Effectiveness of early
antimicrobial treatment was assessed by a Kaplan–Meier estimation of time to recurrence.
Results: Achromobacter xylosoxidans accounted for 13 (38%) of the isolates, and an unnamed species accounted for 11 (32%) of the isolates.
Meropenem, piperacillin–tazobactam and trimethoprim–sulfamethoxazole were highly active against chemotherapy-naïve Achromobacter, while
ceftazidime, colistin and tobramycin were judged adequate for inhalation therapy. Fifty-ﬁve percent of 25 patients treated with inhaled ceftazidime,
colistin, or tobramycin remained free of Achromobacter three years after acquisition, in contrast to 17% of 22 patients who did not receive inhaled
antibiotics (P b 0.01).
Conclusions: Early treatment with inhaled antibiotics may prevent or postpone chronic infection with Achromobacter in CF patients.
© 2013 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reserved.Keywords: Achromobacter xylosoxidans; MLSA; Cross-infections; Systemic therapy; Eradication1. Introduction
Achromobacter species are environmental bacteria isolated
with increasing frequency from respiratory secretions of cystic
fibrosis (CF) patients worldwide [1–3] and are therefore of
growing concern in the CF community. Most studies addressing
the clinical impact of Achromobacter in CF patients conclude
that the infection does not contribute appreciably to clinical⁎ Corresponding author at: Department of Clinical Microbiology,
Brendstrupgaardsvej 100, 8200 Aarhus N, Denmark. Tel.: +45 78455603;
fax: +45 78455611.
E-mail address: nielnoer@rm.dk (N. Nørskov-Lauritsen).
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http://dx.doi.org/10.1016/j.jcf.2013.04.013deterioration [4–7], although colonisationmay be associated with
pulmonary inflammation [8] and increased requirement for
intravenous antibiotics [5]. However, it appears that specific
clones may be associated with increased rates of pulmonary
decline [9,10]. It has recently been shown that several distinct
Achromobacter species are responsible for infection in CF
patients [3,11]; it remains to be shown whether the clinical course
is related to the infecting species.
In addition to concern over clinical impact, experience with
other bacteria in CF supports the notion of early antimicrobial
treatment of Achromobacter. Pseudomonas aeruginosa is a
well-recognized pathogen in CF associated with pulmonary
decline [12,13]. When P. aeruginosa has established a chronicby Elsevier B.V. All rights reserved.
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but early therapy has been shown to postpone or prevent chronic
infection [14–16]. As a result of these findings, early treatment of
P. aeruginosa has become standard treatment of CF care [17]. In
our clinical experience, most patients with Achromobacter have
readily progressed from intermittent to chronic infection, and
when clinical deterioration has necessitated antimicrobial treat-
ment, the bacterium has exhibited a disturbing propensity for
developing pan-resistance to antimicrobial agents.
Due to these considerations, some patients from the Danish
CF clinics have received eradication antimicrobial therapy after
the first detection of Achromobacter in routine sputum samples.
The antimicrobial therapy has not been given systematically
and has consisted of different regimens. In the present report
we have performed extended antibiotic susceptibility testing
of preserved, primary isolates of Achromobacter from CF
patients, and have retrospectively assessed the impact of early
antimicrobial therapy and the time to next occurrence of
Achromobacter.2. Materials and methods
2.1. Patients and study design
In Denmark, CF patient care is centralised to two clinical
centres located at the University hospitals in Aarhus and
Copenhagen. Data were collected through retrospective analysis
of database records of all 457 CF patients who received treatment
at one of the two Danish centres. Surveillance cultures on sputum
or – if the patient is unable to produce sputum – on laryngeal
aspirations from the patients were obtained at monthly visits
to the outpatient clinics. Patients with first acquisition of an
Achromobacter species during the time period from January 1st
2000 to December 31st 2011 were identified and included in the
study. As we intended to investigate antimicrobial susceptibility
and treatment outcome of chemotherapy-naïve Achromobacter,
we excluded all cases of cross-transmission by genotyping with
pulsed-field gel electrophoresis (PFGE). Patients were followed till
end of study period or until next occurrence of Achromobacter.
Retrospective data regarding antimicrobial therapy prescribed after
the first acquisition of Achromobacter were obtained from patient
medical records. Colistin inhalation was administered as 2 million
units twice daily, tobramycin inhalation as 300 mg twice daily,
while ceftazidime inhalation was administered as 2 g in 4 ml
physiological saline twice daily.2.2. Characterisation of primary isolates of Achromobacter
Primary isolates of Achromobacter were identified by partial
sequencing of icd, recA and tyrB, which is an abbreviated version
of our previously published multilocus sequence analysis (MLSA)
scheme for identification of Achromobacter [11]. Concatenated
sequences from individual strains were compared with type and
reference strains of Achromobacter [11]. PFGE was carried out as
described [1].2.3. Antimicrobial susceptibility testing
The susceptibility of primary isolates of Achromobacter to 16
antimicrobials was determined by the Etest (AB bioMerieux,
Solna, Sweden) according to the manufacturer's instructions. The
antimicrobials tested were amikacin, amoxicillin–clavulanate,
aztreonam, cefepime, ceftazidime, ceftriaxone, cefuroxime,
ciprofloxacin, colistin, fosfomycin, imipenem, meropenem,
piperacillin–tazobactam, tigecycline, tobramycin, and trimeth-
oprim/sulfamethoxazole. Susceptibility was interpreted using
the EUCAST breakpoints for Pseudomonas spp. [18].
Breakpoints for inhalation therapy have not been established,
and the susceptibility rates (Table 2) therefore refer to systemic
antibiotic therapy. Because amoxicillin–clavulanate, tigecycline
and trimethoprim/sulfamethoxazole are considered ineffective
against P. aeruginosa, breakpoints are not available for these
agents.2.4. Effectiveness of antimicrobial treatments
Time to next occurrence of Achromobacterwas defined as the
time interval between the first and the second positive sample and
did not require proof of identical genotype of strains. Patients
were grouped according to antimicrobial treatment administered
after primary detection of Achromobacter, and time to next
occurrence was calculated as a Kaplan–Meier estimate. The log
rank test was used to compare outcomes between patients treated
with inhaled antibiotics with those who did not receive inhaled
antibiotics. A p-value of b0.05 was considered statistically
significant.3. Results
3.1. Primary infections with Achromobacter
In the study period (2000–2011), 68 Danish CF patients
experienced a first-time isolation of Achromobacter from their
respiratory secretions and the proportion of Danish CF patients
with at least one positive culture with Achromobacter increased
from 5.2% in 2000 to 11.4% in 2011. One patient received a
lung transplant shortly after infection and was excluded from
the study. Genotyping by PFGE was used to determine
cross-transmission, revealing that 17 of 68 (25%) primary
infections with Achromobacter during the study period were
caused by a recently described clone of Achromobacter
ruhlandii, the Danish Epidemic Strain (DES) [1,9,11]. Kaplan
Meier analysis of time to recurrence showed that one year after
initial detection, none of the patients infected with DES were
free of Achromobacter compared to 46.1% of patients with
non-DES isolates (data not shown). Consequently patients
infected with DES were excluded from the study. Furthermore,
as two small clusters of cross-infection or common-source
infection of two and three patients, respectively, were suspected
based on sequence analysis and confirmed by PFGE, the three
secondarily infected patients were also excluded. Thus a total of
47 primary infections with Achromobacter were included for
640 M. Wang et al. / Journal of Cystic Fibrosis 12 (2013) 638–643analysis of initial antimicrobial treatment and time to next
positive sputum sample with growth of Achromobacter.
Of the 47 primary infections, the first isolate was not stored
from 13 cases. Characterisation and antimicrobial susceptibility
testing were therefore performed on the initial isolate of 34
primary infections with Achromobacter.
3.2. Species distribution and antimicrobial susceptibility of
primary isolates
Achromobacter isolates were identified by partial sequencing
of house-keeping genes icd, recA and tyrB and comparison with
type and reference strains [11]. Achromobacter xylosoxidans
accounted for 13 of 34 (38%) isolates, while Achromobacter
insolitus and A. ruhlandii were represented by a single strain
each (Table 1). Nineteen strains (56%) did not belong to any of
the seven currently named species of genus Achromobacter.
Approximately one third (11 of 34) belonged to a recently
described, putative species, tentatively designated MLSA cluster
III [11].
Antimicrobial susceptibilities of 34 chemotherapy-naïve iso-
lates of Achromobacter are summarised in Table 2. Of 16
antimicrobials tested, the lowest minimum inhibitory concentra-
tions (MICs) were observed for meropenem, piperacillin–
tazobactam, and trimethoprim/sulfamethoxazole. Using EUCAST
clinical breakpoints forPseudomonas species [18], all isolates were
susceptible to piperacillin–tazobactam, 94% were susceptible to
meropenem, and 91% to imipenem. MIC90 for trimethoprim/
sulfamethoxazole was 0.047 mg/L.
Regarding antimicrobials commonly used for inhalation
therapy, colistin and ceftazidime both exhibited good activity
against Achromobacter with MIC90s of 8 and 24 mg/L respec-
tively, while tobramycin showed notably less activity with a
MIC90 of 64 mg/L.
High level resistance to fosfomycin (MIC ≥ 1024 mg/L)
and aztreonam (MIC ≥ 256 mg/L) was observed for all
isolates, and all but two isolates exhibited high level resistance
(MIC ≥ 256 mg/L) to amikacin. Ciprofloxacin displayed
modest inhibitory activity against Achromobacter with only
one isolate being susceptible. However, only five strains expressed
high level resistance to ciprofloxacin (MIC ≥ 32 mg/L) and
treatment with inhaled ciprofloxacin could be a future possibility.
Antimicrobial susceptibility data were analysed for a possible
difference between the twomost frequent species,A. xylosoxidansTable 1
Species distribution of 34 primary Achromobacter isolates from CF patients.
Species No. of strains (%)
A. xylosoxidans 13 (38)
MLSA Cluster III a 11 (32)
MLSA Cluster V a 2 (6)
A. insolitus 1 (3)
A. ruhlandii 1 (3)
Indeterminate b 6 (18)
a As defined [11].
b Strains not clustering with a type or reference strain.and the MLSA cluster III, but no evidence of such a difference
was found (data not shown).
3.3. Primary antimicrobial treatments and time to next
positive culture
Various antimicrobial regimens were instituted after first
acquisition of Achromobacter for a minimum of two weeks.
Antimicrobial agents prescribed were oral amoxicillin–
clavulanate, ciprofloxacin, or trimethoprim/sulfamethoxazole;
intravenously administered (i.v.) aztreonam, ceftazidime,
cefuroxime, colistin, meropenem, piperacillin–tazobactam or
tobramycin; and nebulised, inhaled ceftazidime, colistin or
tobramycin.
Of 47 patients, 25 (53%) were treated with inhaled
ceftazidime, colistin, or tobramycin, while 22 (47%) did not
receive treatment with nebulised antibiotics. All patients treated
with inhaled antibiotics received additional, systemic antimi-
crobial therapy. Of these, 17 received systemic treatment with
i.v. ceftazidime, colistin, meropenem, piperacillin–tazobactam,
or oral trimethoprim/sulfamethoxazole, drugs with activity
against the majority or all Achromobacter strains tested; the
remaining eight patients were treated with oral amoxicillin–
clavulanate or ciprofloxacin, or i.v. aztreonam, cefuroxime or
tobramycin, systemic agents with little or no activity against
Achromobacter. Of 22 patients who did not receive inhaled
antibiotics, 10 patients did not get any antimicrobial therapy,
six patients received systemic therapy with agents active
against Achromobacter, while six patients were treated with
systemic agents with little or no activity against Achromobacter
according to the data presented in Table 2. The number of
patients in the different treatment groups is shown in Table 3.
Fig. 1 shows time to next occurrence of Achromobacter,
comparing patients who were treated with inhaled antibiotics to
patients who did not receive treatment with inhaled antibiotics.
Of 25 patients initially treated with inhaled antibiotics, 55% were
free of Achromobacter three years after the primary detection,
while the corresponding proportion for the 22 patients who did
not receive initial treatment with inhaled antibiotics was 17%
(log rank p b 0.01). Patient characteristics for two groups are
shown in Table 4.
Regarding the effect of systemic therapy, Kaplan–Meier
estimates for the proportion of patients remaining free of
Achromobacter for three years according to treatment regimen
are shown in Table 5. In patients treated with inhaled antibiotics,
the proportion free of Achromobacter was slightly higher (58 vs.
50%) if potentially active systemic therapy had been given. In
patients not treated with inhaled antibiotics, the proportion free of
Achromobacter after three years was 17% if systemic therapy had
been given, while 14% of patients who did not receive any
antimicrobial agents were free of Achromobacter for three years.
However, it should be emphasised that the subgroup analysis is
based on very few patients and therefore tests of significance
were not performed.
Restricting calculations to 34 preserved and confirmed
isolates of Achromobacter, 56% of 18 patients who received
inhalation therapy with ceftazidime, colistin, or tobramycin
Table 2
Antimicrobial susceptibility of 34 primary Achromobacter isolates from CF patients.
Antimicrobial agent MIC50
a MIC90
b Range Geometric mean c % Susceptible d
Amikacin ≥256 ≥256 12 to ≥256 198.1 0
Amoxicillin–clavulanate 6 ≥256 2 to ≥256 7.2 N/A e
Aztreonam ≥256 ≥256 ≥256 256 0
Cefepime 32 ≥256 2 to ≥256 34.3 21
Ceftazidime 6 24 1.5–48 7.4 62
Ceftriaxone ≥32 ≥32 ≥32 32 N/A
Cefuroxime ≥256 ≥256 ≥256 256 N/A
Ciprofloxacin 2 ≥32 0.5 to ≥32 3.5 3
Colistin 4 8 0.38–16 3.0 74
Fosfomycin ≥1024 ≥1024 ≥1024 1024 N/A
Imipenem 2 8 0.75 to ≥32 2.4 92
Meropenem 0.125 1.5 0.064 to ≥32 0.2 94
Piperacillin/tazobactam 1 2 0.38–6 0.9 100
Tigecycline 3 4 0.19–8 2.0 N/A
Tobramycin 24 64 1.5–96 18.4 9
Trimethoprim/sulfamethoxazole 0.016 0.047 0.006 to ≥32 0.02 N/A
a Minimum inhibitory concentrations in mg/L for 50% of isolates.
b Minimum inhibitory concentrations in mg/L for 90% of isolates.
c Isolates reaching the upper level of assay (≥) were included at this level in the calculation of geometric means.
d Interpreted according to EUCAST susceptibility breakpoints for Pseudomonas species.
e Breakpoint not available.
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of 16 patients who were not treated with inhaled antibiotics.
Kaplan Meier analysis of time to recurrence did not reveal any
species specific difference between the two most frequent
species, A. xylosoxidans and MLSA cluster III.
4. Discussion
We investigated primary infections with Achromobacter in
the two Danish CF centres over a 12-year period. Strains
acquired by patient-to-patient transmission have usually been
exposed to antimicrobial agents and may exhibit acquired
antimicrobial resistance. The Danish epidemic strain (DES) is a
transmissible strain that has spread between patients from the
two centres [1,9,11] causing 25% of primary infections with
Achromobacter in Danish CF patients during the study period.
The DES is, or has become, an exceptionally resistant clone of
Achromobacter, and infection with DES is suspected if an
initial isolate of Achromobacter exhibits pan-resistance. As weTable 3
Antimicrobial treatments received by 47 patients after the first acquisition of
Achromobacter.
N (%)
Inhaled antibiotics a No inhaled antibiotics
Systemic antimicrobial therapy 25 (100%) 12 (55%)
Potentially active b 17 (68%) 6 (28%)
Other antimicrobials c 8 (32%) 6 (28%)
No systemic therapy 0 (0%) 10 (45%)
a Inhaled ceftazidime, colistin, tobramycin.
b Ceftazidime i.v., colistin i.v., meropenem i.v., piperacillin–tazobactam i.v.,
oral trimethoprim–sulfamethoxazole.
c Oral amoxicillin–clavulanate, aztreonam i.v., cefuroxime i.v., oral ciprofloxacin,
tobramycin i.v.have found that patients infected with DES rapidly progress to
chronic infection compared to patients infected with non-DES
isolates, we excluded all cases of documented or suspected
cross-infections. We found 47 primary infections without signs
of patient-to-patient transmission, and from 34 of 47 infections,
the first isolate was preserved and available for investigation.
It has recently become clear that multiple species of
Achromobacter are able to infect or chronically colonise patients
with CF [3,11]. A. xylosoxidans accounted for less than half (13 of
34) of primary infections in Denmark, in accordance with recently
published data from the U.S. [3]. Almost one third (11 of 34) ofInhaled antibiotics
No inhaled antibiotics
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Fig. 1. Cumulative proportion of patients who remained free of Achromobacter
in relation to initial treatment with inhaled antimicrobials. Solid line, patients
treated with inhaled ceftazidime, colistin or tobramycin (N = 25); dotted line,
patients not receiving initial treatment with inhaled antimicrobials (N = 22).
Log rank p value b 0.01.
Table 4
Patient characteristics at initial Achromobacter detection.
Treated with inhaled
antimicrobials (N = 25)
Not treated with inhaled
antimicrobials (N = 22)
Gender (males) 6 11
Mean age (years) 15.0 (range 3–28) 17.3 (range 0–31)
CF centre
- Aarhus 7 12
- Copenhagen 18 10
Mean FEV1
(% predicted)
N = 42
75.6
(range 31.9–105.5)
66.1
(18.3–106.8)
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tentatively designatedMLSA cluster III [11]. Preliminary analysis
suggests that this cluster corresponds toAchromobacter genogroup
2 of Spilker et al. [19], which accounted for less than 5% of
Achromobacter isolates in American CF patients [3]. The different
prevalences of MLSA cluster III/Achromobacter genogroup 2 in
Danish and American CF patients could result from exposure to
different pools of bacteria determined by local environments;
however, the reported distribution of Achromobacter species from
American CF patients has not been corrected for patient-to-
patient transmissions. With the Burkholderia cepacia complex,
the initial predominance of Burkholderia cenocepacia was partly
caused by the introduction of epidemic clones of this species,
which spread widely within and between clinics. After intro-
duction of segregation policies, a shift toward Burkholderia
multivorans has been observed [20,21].
Achromobacter species have been reported to be multidrug-
resistant organisms in the context of CF [6,22,23]. However,
when analysis is restricted to chemotherapy-naïve isolates, a
number of antimicrobial agents showed high inhibitory activity
against Achromobacter (Table 2). Lowest MIC90s were observed
for meropenem, piperacillin–tazobactam, and trimethoprim/
sulfamethoxazole, making these antibiotics attractive treatment
options for systemic therapy of early Achromobacter colonisa-
tion. Ceftazidime and colistin showed somewhat reduced
activity, with susceptibility rates of 62–74% (Table 2). MIC90
for tigecycline was 4 mg/L; tigecycline is susceptible to the
multidrug efflux systems found in P. aeruginosa [24], and
consequently no breakpoint has been recommended. A non-Table 5
Proportion of 47 patients remaining free of Achromobacter for 3 years.
Systemic
antimicrobial
treatment
Achromobacter-free
proportion
No. at
risk
Treatment with inhaled
antibioticsa
Potentially activea 58% 17
Other antimicrobialsa 50% 8
All patients 55% 25
No treatment with inhaled
antibiotics
Potentially activea 17% 6
Other antimicrobialsa 17% 6
No systemic therapy 14% 10
All patients 17% 22
a See Table 3 for grouping of antimicrobials.species related breakpoint of 0.25 mg/L [18] suggests
Achromobacter to be a poor target for therapy with tigecycline.
Likewise no breakpoint for amoxicillin–clavulanate is available
for Pseudomonas species, but a non-species related breakpoint
of 2 mg/L [18] implies that amoxicillin–clavulanate with a
MIC90 of ≥256 mg/L is of limited value as therapy against
Achromobacter. All isolates exhibited high level resistance
to aztreonam and fosfomycin, indicating that Achromobacter
species may be inherently resistant to these two antimicrobial
agents.
The reported innate resistance of Achromobacter to
aminoglycosides [23,25] was only partly confirmed. High
level resistance to amikacin was noted for almost all isolates,
but three strains were fully susceptible to tobramycin by
EUCAST breakpoints (MIC ≤ 4 mg/L). Tobramycin is com-
monly used for inhalation therapy, although breakpoints for
this mode of administration have not been defined. We ob-
served a MIC90 of 64 mg/L and a maximal MIC of 96 mg/L for
tobramycin against primary isolates of Achromobacter. All
isolates were interpreted as treatable by tobramycin inhalation
therapy with the use of a locally defined breakpoint of 100 mg/L
for tobramycin. This breakpoint should be viewed in light of peak
sputum concentrations of approximately 1200 μg/g after inhala-
tion of 300 mg tobramycin [26]. When taking the optimal 10:1
peak/MIC ratio of aminoglycosides into account [27], this
roughly translates into a breakpoint of 100 mg/L. We consider
ceftazidime, colistin and tobramycin to be feasible treatment
options for inhalation therapy of early Achromobacter colonisa-
tion, while aztreonam cannot be recommended.
Ten of 47 patients did not receive treatment with antimicrobial
agents in response to the first detection of Achromobacter in
sputum cultures, while a number of different regimens were
prescribed to 37 patients. Due to the small number of patients
we cannot assess the merits of individual treatments, but by
combining similar regimens it is possible to extract some indication
of effectiveness from the data. A large and significant difference
was observed between 25 patients who were treated with inhaled
ceftazidime, colistin, or tobramycin, and 22 patients who did not
receive inhaled antibiotics: three years after initial acquisition, 55%
of treated patients remained free of Achromobacter colonisation in
contrast to 17% of untreated patients. The difference cannot be
ascribed solely to the prescription of inhalation therapy, as the
majority of patients treated with inhaled antibiotics received
simultaneous systemic antimicrobial therapy with activity against
Achromobacter. However, data analysis failed to show an obvious
effect of systemic therapy in the absence of inhalation therapy
(Table 5). Although this analysis is based on few patients, the
relationship between inhalation therapy and postponement of
next occurrence of Achromobacter is in line with experience with
P. aeruginosa, where randomised trials have shown efficacy of
inhaled tobramycin in the absence of concurrent systemic therapy
[28–31]. In addition to the limitations of a retrospective study, our
data may be biassed by differences in duration of the initial
treatment, or by subsequent antimicrobial treatments. Nonetheless,
until prospective, randomised studies of early Achromobacter
infection become available, our data suggest an antibiotic regimen
consisting of inhaled ceftazidime, colistin or tobramycin to be a
643M. Wang et al. / Journal of Cystic Fibrosis 12 (2013) 638–643reasonable strategy to postpone or prevent subsequent occurrence
of Achromobacter in sputum from CF patients.
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